Endometriosis Market Poised to Hit $2.21 Billion by 2029 with Accelerating Growth Trends

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Endometriosis Market Size Growth Forecast: What to Expect by 2025?
The global endometriosis market has experienced significant expansion lately, projected to increase its valuation from $1.4 billion in 2024 to $1.54 billion in 2025, reflecting a robust compound annual growth rate of 9.8%; this upward trend during the past period stemmed from factors such as heightened public and professional awareness, the longer intervals before diagnosis occurred, improvements in minimally invasive laparoscopic surgical techniques, developments in hormonal treatment options, and the rising influence of patient advocacy as well as support networks.

How Will the Endometriosis Market Size Evolve and Grow by 2029?
Anticipation is high for substantial expansion within the endometriosis market over the coming years, projecting a valuation of $2.21 billion by 2029, driven by a compound annual growth rate (CAGR) settling at 9.4%. This upward trajectory in the projected timeframe is fundamentally supported by advancements in less invasive surgical techniques, breakthroughs in pharmaceutical development, intensive studies into genetics and epigenetics, and the worldwide broadening of women's health services. Key shifts shaping the outlook during this period encompass a focus on care tailored to individual patients, the adoption of precision medicine approaches, the integration of virtual services and remote consultations, and increasing emphasis on preserving fertility options.

View the full report here:
https://www.thebusinessresearchcompany.com/report/endometriosis-global-market-report

What Drivers Are Propelling the Growth of Endometriosis Market Forward?
The rising prevalence of ovarian cancer is anticipated to be a key factor boosting the expansion of the endometriosis market in the near future. Ovarian cancer originates in the ovaries, which are the female organs responsible for egg production and the secretion of hormones such as estrogen and progesterone. A demonstrable link exists between endometriosis and a heightened susceptibility to epithelial ovarian cancer, particularly the endometrioid and precise cell subtypes, largely because elevated estrogen levels associated with the condition elevate cancer risk. To illustrate this, projections released in January 2023 by the American Cancer Society, a US professional body, estimated around 19,710 new ovarian cancer diagnoses among US women for that year. Additionally, the Ovarian Cancer Research Alliance, a US non-profit organization, reported that ovarian cancer accounted for 12,810 fatalities in 2022, with this figure climbing to 13,270 deaths the following year in 2023. Consequently, the escalating rate of ovarian cancer diagnoses is serving as a growth stimulant for the overall endometriosis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13035&type=smp

Which Emerging Trends Are Transforming the Endometriosis Market in 2025?
Key players within the endometriosis sector are concentrating efforts on pioneering therapeutic agents, exemplified by Myfembree, and securing regulatory clearances to furnish patients with novel avenues for care. The arrival of these new pharmaceutical solutions directly responds to the substantial, previously unfulfilled need for efficacious therapeutic strategies. Notably, a significant milestone was reached in August 2022 when Myovant Sciences GmbH, headquartered in Switzerland, alongside the American pharmaceutical giant Pfizer Inc., obtained authorization from the US Food and Drug Administration (FDA) to market Myfembree for alleviating moderate to severe discomfort linked to endometriosis in women who have not yet reached menopause. This medication, administered orally once a day, integrates three core components: relugolix, estradiol, and norethindrone acetate, thereby offering demonstrable symptomatic improvement for premenopausal women through its dual-indication formulation in a single tablet, presenting a viable alternative for those unable or unwilling to pursue conventional hormone-based interventions.

What Are the Key Segments in the Endometriosis Market?
The endometriosismarket covered in this report is segmented -

1) By Type: Superficial Peritoneal Lesion; Endometrioma; Deeply Infiltrating Endometriosis; Other Types
2) By Treatment Type: Hormonal Therapy; Pain Management
3) By Drug: Oral Contraceptives; Progestins; Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Gonadotropin Releasing Hormone (GnRH) Analogues; Levonorgestrel-Releasing Intrauterine Devices (LNR-IUDs); Other Drugs
4) By End-User: Hospitals; Homecare; Specialty Centers; Other End-Users

Subsegments:
1) By Superficial Peritoneal Lesion: Endometriotic Nodules; Peritoneal Endometriosis
2) By Endometrioma: Chocolate Cysts
3) By Deeply Infiltrating Endometriosis: Bowel Endometriosis; Ureteral Endometriosis; Vaginal Endometriosis
4) By Other Types: Abdominal Endometriosis; Thoracic Endometriosis

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13035&type=smp

Who Are the Key Players Shaping the Endometriosis Market's Competitive Landscape?
Major companies operating in the endometriosis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck And Co. Inc., Abbvie Inc., Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, AstraZeneca PLC, Abbott Laboratories, Eli Lilly and Company, Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Ipsen Pharma Biotech S.A.S., Cadila Pharmaceuticals Ltd., Gedeon Richter PLC, Torrent Pharmaceuticals Ltd., Neurocrine Biosciences Inc., Ferring Pharmaceuticals, Prestige Consumer Healare Inc., Almirall S.A, Evotec BioSystems GmbH, Serum Institute of India Pvt. Ltd., Kissei Pharmaceutical Co. Ltd., Sanofi India Ltd., DebioPharm Group, Repros Therapeutics Inc., Meditrina Pharmaceuticals Private Limited, Zenomed Healare Private Limited.

What Geographic Markets Are Powering Growth in the Endometriosis Market?
North America was the largest region in the endometriosis market in 2024. The regions covered in endometriosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13035

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.